Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Dow
Boehringer Ingelheim
Medtronic
McKinsey

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

HIBICLENS Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Hibiclens patents expire, and when can generic versions of Hibiclens launch?

Hibiclens is a drug marketed by Molnlycke Hlth and is included in two NDAs.

The generic ingredient in HIBICLENS is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-eight suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.

Drug patent expirations by year for HIBICLENS
Drug Sales Revenue Trends for HIBICLENS

See drug sales revenues for HIBICLENS

Paragraph IV (Patent) Challenges for HIBICLENS
Tradename Dosage Ingredient NDA Submissiondate
HIBICLENS SPONGE;TOPICAL chlorhexidine gluconate 018423

US Patents and Regulatory Information for HIBICLENS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SOLUTION;TOPICAL 017768-001 Approved Prior to Jan 1, 1982 OTC Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SPONGE;TOPICAL 018423-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for HIBICLENS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SOLUTION;TOPICAL 017768-001 Approved Prior to Jan 1, 1982 ⤷  Free Forever Trial ⤷  Free Forever Trial
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SPONGE;TOPICAL 018423-001 Approved Prior to Jan 1, 1982 ⤷  Free Forever Trial ⤷  Free Forever Trial
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SPONGE;TOPICAL 018423-001 Approved Prior to Jan 1, 1982 ⤷  Free Forever Trial ⤷  Free Forever Trial
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SPONGE;TOPICAL 018423-001 Approved Prior to Jan 1, 1982 ⤷  Free Forever Trial ⤷  Free Forever Trial
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SOLUTION;TOPICAL 017768-001 Approved Prior to Jan 1, 1982 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Boehringer Ingelheim
Baxter
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.